Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Hansa Biopharma

23.18

 

SEK

 

-0.52 %

Less than 1K followers

HNSA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-0.52%
-13.25%
-11.46%
-40.87%
-28.68%
-45.69%
-61.65%
-81.54%
+212.59%

Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Read more
Market cap
1.57B SEK
Turnover
3.31M SEK
Revenue
171.32M
EBIT %
-372.03 %
P/E
-
Dividend yield-%
-
Financial calendar
25/6
2025

General meeting '25

17/7
2025

Interim report Q2'25

23/10
2025

Interim report Q3'25

All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release5/26/2025, 4:40 PM

Hansa Biopharma AB: Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency

Hansa Biopharma
Regulatory press release5/26/2025, 4:40 PM

Hansa Biopharma AB: Hansa Biopharma planerar omstrukturering för att optimera resursfördelning och förbättra operationell effektivitet

Hansa Biopharma
Regulatory press release5/26/2025, 5:00 AM

Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/26/2025, 5:00 AM

Kallelse till årsstämma i Hansa Biopharma AB (publ)

Hansa Biopharma
Press release5/14/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Hansa Biopharma
Press release5/13/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.

Hansa Biopharma
Press release5/13/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma utser Maria Törnsén till Chief Operating Officer och President U.S.

Hansa Biopharma
Press release4/29/2025, 7:11 AM

Redeye: Hansa Biopharma update - The European launch regains momentum

Hansa Biopharma
Regulatory press release4/24/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results

Hansa Biopharma
Regulatory press release4/24/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma redovisar resultat för första kvartalet och delårsperioden januari-mars 2025

Hansa Biopharma
Regulatory press release4/24/2025, 5:00 AM

Hansa Biopharma AB: Hansa Biopharma appoints new Chief Executive Officer

Hansa Biopharma
Regulatory press release4/24/2025, 5:00 AM

Hansa Biopharma AB: Hansa Biopharma utser ny VD

Hansa Biopharma
Press release4/3/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2025

Hansa Biopharma
Press release4/3/2025, 6:00 AM

Hansa Biopharma AB: Hansa Biopharma to host Q1 2025 interim results conference call

Hansa Biopharma
Press release3/25/2025, 8:00 AM

Hansa Biopharma AB: Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference

Hansa Biopharma
Regulatory press release3/21/2025, 2:00 PM

Hansa Biopharma AB: Hansa Biopharma publishes 2024 Annual and Sustainability Reports

Hansa Biopharma
Regulatory press release3/21/2025, 2:00 PM

Hansa Biopharma AB: Hansa Biopharma publicerar årsredovisning och hållbarhetsredovisning för 2024

Hansa Biopharma
Press release3/11/2025, 1:35 PM

Hansa Biopharma AB: Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma
Press release3/4/2025, 7:00 AM

Hansa Biopharma AB: Hansa Biopharma to attend Leerink Partners Global Healthcare Conference

Hansa Biopharma
Press release2/24/2025, 7:00 AM

Hansa Biopharma AB: Hansa Biopharma to attend TD Cowen Healthcare Conference

Hansa Biopharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team